Abstract
Omalizumab is recently developed monoclonal anti-IgE antibody. Clinical trials have demonstrated its efficacy in patients with moderate-to-severe and severe or poorly controlled allergic asthma, in patients with seasonal and perennial allergic disease and in subjects with concomitant asthma and allergic rhinitis. Patients with more severe asthma appear to obtain the greatest benefit from omalizumab therapy. Omalizumab is well tolerated and has a good safety profile. Anti-inflammatory activity has been shown in both allergic asthma and allergic rhinitis [1,2]. Omalizumab is not a firstline therapy in asthmatic patients. FDA (Food and Drug Administration ) approved omalizumab use in June of 2003 for patients satisfying the following criteria (all must be present): 1- total IgE concentration in serum 30-700 klU L. 2- skin test positive for at least one perennial allergen; 3- specific IgE concentration positive for at least one perennial allergen (house dust mite, cat and dog); 4- asthma: moderate to severe persistent asthma; 5- age: > 12 years; 6- inadequate control despite inhaled corticosteroids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy
Volume: 7 Issue: 1
Author(s): I. Olcay
Affiliation:
Abstract: Omalizumab is recently developed monoclonal anti-IgE antibody. Clinical trials have demonstrated its efficacy in patients with moderate-to-severe and severe or poorly controlled allergic asthma, in patients with seasonal and perennial allergic disease and in subjects with concomitant asthma and allergic rhinitis. Patients with more severe asthma appear to obtain the greatest benefit from omalizumab therapy. Omalizumab is well tolerated and has a good safety profile. Anti-inflammatory activity has been shown in both allergic asthma and allergic rhinitis [1,2]. Omalizumab is not a firstline therapy in asthmatic patients. FDA (Food and Drug Administration ) approved omalizumab use in June of 2003 for patients satisfying the following criteria (all must be present): 1- total IgE concentration in serum 30-700 klU L. 2- skin test positive for at least one perennial allergen; 3- specific IgE concentration positive for at least one perennial allergen (house dust mite, cat and dog); 4- asthma: moderate to severe persistent asthma; 5- age: > 12 years; 6- inadequate control despite inhaled corticosteroids
Export Options
About this article
Cite this article as:
Olcay I., Anti-Immunoglobulin E Treatment with Omalizumab in Allergic Diseases an Update on Anti-Inflammatory Activity and Clinical Efficacy, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (1) . https://dx.doi.org/10.2174/187152308783769131
DOI https://dx.doi.org/10.2174/187152308783769131 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Natural Products and Colon Drug Delivery ]
Current Drug Delivery Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Synthesis and Biological Study of Novel Indole-3-Imine-2-on Derivatives as Src Kinase and Glutathione S-Transferase Inhibitors
Letters in Drug Design & Discovery Acupuncture and Asthma: Ancient Technique that Survives Advances in Medicine
Current Respiratory Medicine Reviews Allergoids for Allergy Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Primaquine Loaded Chitosan Nanoparticles For Liver Targeting
Pharmaceutical Nanotechnology Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology
Current Pharmaceutical Design Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD
Current Drug Targets New Insights into the Immune Response to Pneumococci
Current Respiratory Medicine Reviews Uleine Disrupts Key Enzymatic and Non-Enzymatic Biomarkers that Leads to Alzheimer’s Disease
Current Alzheimer Research Nature: A Substantial Source of Auspicious Substances with Acetylcholinesterase Inhibitory Action
Current Neuropharmacology Dietary Interventions in Asthma
Current Pharmaceutical Design Mast Cells At Mucosal Frontiers
Current Molecular Medicine New Uses of Melatonin as a Drug; A Review
Current Medicinal Chemistry Inflammation in Asthma Pathogenesis: Role of T Cells, Macrophages, Epithelial Cells and Type 2 Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Camptothecins and Lung Cancer: Improved Delivery Systems by Aerosol
Current Cancer Drug Targets Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism Recent Advancement and Technological Aspects of Pulsatile Drug Delivery System - A Laconic Review
Current Drug Targets The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents